Coronary Clot Aspiration Safe Long Term
After certain types of heart attacks, doctors often use stents to prop open the arteries. Another method that may be used involves removing blood clots through thrombus aspiration (TA), but studies have shown mixed long-term results.
Do Concrete and Smog Create Heart Risks?
Living in a big city may have its benefits when it comes to convenience, but a new study reveals added pollution may not be doing any favors for your heart.
Predicting Heart Attacks
The ability to predict and prevent heart attacks is considered the holy grail in cardiology. Scientists may not be there yet, but they've taken another bold step toward prediction in a new clinical trial.
Inflammation Protein Tied to Gum Disease
Your gum health may be more closely linked to your cardiovascular system than you know. A protein associated with cellular inflammation appears to raise the risk of chronic gum disease.
Gum Disease Doesn't Cause Heart Disease
Though they share common risk factors, gum disease does not appear to cause heart disease or stroke. A new statement also reveals that treating gum disease is not proven to prevent stroke or plaque build up in the heart.
Spice Lowers Heart Attack Risk After Surgery
An Indian spice popular in curry appears to offer the heart a protective benefit following coronary artery bypass grafting. New research suggests turmeric may help prevent heart attacks after the operation.
Stents Safe for Metal Allergy Patients
For patients with allergies to metals such as nickel, metal stents to open arteries and improve blood flow to the heart had proved troubling for cardiologists treating their coronary artery disease.
Biodegradable Stents Safe Long Term
A lengthy study has found that experimental biodegradable coronary artery stents, designed to prop open clogged coronary arteries to increase blood flow, are safe long term.
Fatty Foods Damage Arteries Early
Consuming a high fat diet doesn't just cause you to pack on the pounds. It also may prematurely damage your blood vessels, which could lead to high blood pressure and coronary artery disease.
Sanofi and Regeneron Report Phase 2 Results for Lipid Drug
Sanofi and Regeneron Pharmaceuticals, Inc. announced that data from two Phase 2 trials with SAR236553 / REGN727 , an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 ( proprotein convertasesubtilisin / kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.